Assessing agonistic potential of a candidate therapeutic anti-IL21R antibody

Table 1 Summary of assays performed

		Daudi	D1	D2-D3	D4-D5	D6-D10	D11-D15
Coating	wet	-/+	+/+	-/-	-/-	-/-	-/-
	dry	-/+	+/+	+/+	+/+	+/+	+/+
	anti-IgG	-/+	+/+	+/+	+/+	+/+	-/-
Positive controls	rhIL21	-/+	+/+	+/+	+/+	+/+	+/+
	Anti-CD28	-/-	-/-	-/-	-/-	+/+	+/+
Negative controls	IgG₁TM	-/+	+/+	+/+	+/+	+/+	+/+
	IgG₁/Fc	-/-	-/-	+/+	-/-	-/-	-/-
Testing antibody	Ab-01 10 μg/well	-/-	-/-	-/-	-/-	+/+	-/-
	Ab-01 <10 μg/well	-/+	+/+	+/+	+/+	+/+	-/-

Assay performed on PBMCs from each of 15 healthy human donors. D indicates "donor". + indicates that assay was performed. - indicates that assay was not performed. Left of/indicates RNA. Right of/indicates protein.

ISSN: 1479-5876